Cell Reprogramming

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of cell reprogramming (iPSC generation) / direct reprogramming service and products market and their likely evolution in the short-mid term and long term. 

Chapter 3 provides a general overview of stem cell-based therapies, their classification and applications. In addition, it features a detailed discussion on cell reprogramming, including information on different cell reprogramming services. It provides information on the various cell reprogramming technologies available for the generation of iPSCs and their potential usability across different application areas. Further, the chapter includes a discussion on the key growth drivers and roadblocks to cell reprogramming.

Chapter 4 provides a review of the global cell reprogramming services and products market landscape. It includes information related to more than 30 players that are currently active in this domain. In addition, it features a detailed analysis of players based on the parameters, such as type of  service, type of offering, type of technology offered, type of vector used, source cell for iPSC generation, target indication(s), type of application and type of additional service(s) offered. The chapter also highlights the academic players that provide stem cell reprogramming services and products. Furthermore, we have presented the contributions of various stakeholders that are developing affiliated products required for cell reprogramming.

Chapter 5 features an insightful competitiveness analysis of both iPSC generation and direct reprogramming service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on a company’s employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation, number of target indications and number of manufacturing facilities).

Chapter 6 provides elaborate profiles of all industry players that are currently engaged in the cell reprogramming domain. Each profile features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook. 

Chapter 7 features a detailed analysis of the partnerships / collaborations that have been inked amongst the players in this market. It includes a brief description on the various types of partnership models (such as product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others) that have been adopted by stakeholders in this domain, and analysis on the trend of partnerships inked since 2016. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to cell reprogramming. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 provides a detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials

Chapter 9 presents a list of stem cell therapy developers / manufacturers that are anticipated to partner with cell reprogramming service and product providers in the foreseen future. The list was prepared based on an in-depth analysis of potential stakeholders, taking into consideration multiple parameters, such as company size (employee count), type of cell (s), indication count and existing partnership(s).

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the cell reprogramming (iPSC generation) / direct reprogramming services and products market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cell for iPSC generation (fibroblast, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world).

Chapter 11 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Cristiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics) and Julien Maruotti (Chief Scientific Officer, Phenocell).

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cells
3.2.1. Classification of Stem Cells
3.2.1.1. Based on Source of Stem Cell
3.2.1.2. Based on Origin of Stem Cell
3.2.1.3. Based on Potency of Stem Cell
3.2.2. Routes of Administration of Stem Cell Therapies
3.2.3. Applications of Stem Cell Therapies

3.3. Introduction to Cell Reprogramming
3.3.1. Cell Reprogramming Approaches and Affiliated Technologies

3.4. Applications of Cell Reprogramming
3.5. Key Growth Drivers and Constraints

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Reprogramming Service and Product Providers: List of Industry Players

4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Location of Stem Cell Research Facilities
4.2.5. Analysis by Type of Service
4.2.6. Analysis by Type of Technology
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Source Cell
4.2.9. Analysis by Application Area
4.2.10. Analysis by Additional Service(s) Offered
4.2.11. Analysis by Type of Offering

4.3. Cell Reprogramming Service and Product Providers: List of Non-Industry Players
4.3.1. Analysis by Geographical Location
4.3.2. Analysis by Type of Technology Used
4.3.3. Analysis by Source Cell for iPSC Generation
4.3.4. Analysis by Type of Offering

4.4. Cell Reprogramming: List of Affiliated Products Providers

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis: iPSC Generation Service and Product Providers
5.5. Competitiveness Analysis: Direct Reprogramming Service and Product Providers

6. COMPANY PROFILES
6.1. Chapter Overview

6.2. Allele Biotechnology
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook

6.3. ALSTEM
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Applied Biological Materials
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Axol Bioscience
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook

6.6. Creative Bioarray
6.6.1. Company Overview
6.6.1.1. Recent Developments and Future Outlook

6.7. DefiniGEN
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook

6.8. FUJIFILM Cellular Dynamics International
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook

6.9. Lonza
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook

6.10. Mogrify
6.10.1. Company Overview
6.10.2. Recent Developments and Future Outlook

6.11. REPROCELL
6.11.1. Company Overview
6.11.1.1. Recent Developments and Future Outlook

6.12. Stemnovate
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook

6.14. Thermo fisher Scientific
6.14.1. Company Overview
6.14.1.1. Recent Developments and Future Outlook

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Stem Cell Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
7.3.8. Analysis by Trial Focus
7.3.9. Analysis by Type of Stem Cell
7.3.10. Analysis by Therapeutic Area
7.3.11. Analysis by Type of Stem Cell and Therapeutic Area
7.3.12. Geographical Analysis by Number of Clinical Trials
7.3.13. Geographical Analysis by Trial Recruitment Status
7.3.14. Geographical Analysis by Enrolled Patient Population

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Cell Reprogramming Services and Products Market: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Analysis by Type of Stem Cell
8.3.6. Analysis by Target Therapeutic Area
8.3.7. Analysis by Application
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Regional Analysis
8.3.10. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNERSHIP OPPORTUNITIES
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Stem Cell Therapy Developers: Likely Partners for Cell Reprogramming Service and Product Providers
9.4.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
9.4.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
9.4.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

9.5. Stem Cell Therapy Contract Manufacturers: Likely Partners for Cell Reprogramming Service and Product Providers
9.5.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
9.5.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
9.5.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Forecast Methodology and Key Assumptions
10.4. Global Cell Reprogramming Services and Products Market, 2020-2030
10.4.1. Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
10.4.1.1. Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030
10.4.1.2. Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030
10.4.1.3. Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030
10.4.1.4. Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030

10.4.2. Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
10.4.2.1. Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030
10.4.2.2. Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030
10.4.2.3. Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030
10.4.2.4. Cell Reprogramming Services and Products Market for Other Cells, 2020-2030

10.4.3. Global Cell Reprogramming Services and Products Market: Distribution by End-User, 2020-2030
10.4.3.1. Cell Reprogramming Services and Products Market for Industry Players, 2020-2030
10.4.3.2. Cell Reprogramming Services and Products Market for Non-Industry Players, 2020-2030

10.4.4. Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
10.4.4.1. Cell Reprogramming Services and Products Market in North America, 2020-2030
10.4.4.2. Cell Reprogramming Services and Products Market in Europe, 2020-2030
10.4.4.3. Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Asgard Therapeutics
11.2.1. Company Snapshot
11.2.2. Cristiana Pires, Co-Founder and Chief Executive Officer

11.3. Phenocell
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Julien Maruotti, Chief Scientific Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Cellular Lineages used for Isolation of Stem Cells
Figure 3.2 Steps Involved in the Development and Administration of Stem Cells
Figure 3.3 Classification of Stem Cells
Figure 3.4 Classification based on Source of Stem Cell
Figure 3.5 Differences between Allogeneic and Autologous Stem Cell Therapies
Figure 3.6 Classification of Stem Cells based on Origin
Figure 3.7 Classification of Adult Stem Cells
Figure 3.8 Classification based on Potency of Stem Cell
Figure 3.9 Key Application Areas for Stem Cell Therapies
Figure 3.10 Potential Applications of Cell Reprogramming
Figure 3.11 Key Growth Drivers and Constraints to Cell Reprogramming
Figure 4.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
Figure 4.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
Figure 4.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 4.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
Figure 4.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
Figure 4.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
Figure 4.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
Figure 4.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
Figure 4.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
Figure 4.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation and Company size
Figure 4.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
Figure 4.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Directly Reprogrammed cells
Figure 4.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
Figure 4.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
Figure 4.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
Figure 4.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
Figure 4.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
Figure 5.1 Competitiveness Analysis of iPSCs Generation Service and Product Providers
Figure 5.2 Competitiveness Analysis of Direct Reprogramming Service and Product Providers
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Trial Registration Year, 2011-2019
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.9 Clinical Trial Analysis: Leading Industry Players
Figure 7.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
Figure 7.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 7.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Stem Cell
Figure 8.6 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution by Application
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Regional Analysis
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreement
Figure 10.1 Global Cell Reprogramming Services and Products Market, 2020-2030 (USD Million)
Figure 10.2 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
Figure 10.3 Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030 (USD Million)
Figure 10.4 Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030 (USD Million)
Figure 10.5 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030 (USD Million)
Figure 10.6 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030 (USD Million)
Figure 10.7 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
Figure 10.8 Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030 (USD Million)
Figure 10.9 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030 (USD Million)
Figure 10.10 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030 (USD Million)
Figure 10.11 Cell Reprogramming Services and Products Market for Other Cells, 2020-2030 (USD Million)
Figure 10.12 Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
Figure 10.13 Cell Reprogramming Services and Products Market for Research, 2020-2030 (USD Million)
Figure 10.14 Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030 (USD Million)
Figure 10.15 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
Figure 10.16 Cell Reprogramming Services and Products Market in North America, 2020-2030 (USD Million)
Figure 10.17 Cell Reprogramming Services and Products Market in Europe, 2020-2030 (USD Million)
Figure 10.18 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Differences between Stem Cell Therapies and Other Biologics
Table 4.1 Cell Reprogramming Services and Products: List of Industry Players
Table 4.2 Cell Reprogramming Services and Products: List of Non-Industry Players
Table 4.3 Cell Reprogramming Services and Products: List of Affiliated Product Providers
Table 6.1 Cell Reprogramming Service and Product Providers: List of Profiled Companies
Table 6.2 ALSTEM: Company Snapshot
Table 6.3 ALSTEM: Recent Developments and Future Outlook
Table 6.4 Applied Biological Materials: Company Snapshot
Table 6.5 Applied Biological Materials: Recent Developments and Future Outlook
Table 6.6 Axol Bioscience: Company Snapshot
Table 6.7 Axol Bioscience: Recent Developments and Future Outlook
Table 6.8 Creative Bioarray: Company Snapshot
Table 6.9 Creative Bioarray: Recent Developments and Future Outlook
Table 6.10 DefiniGEN: Company Snapshot
Table 6.11 DefiniGEN: Recent Developments and Future Outlook
Table 6.12 FUJIFILM Cellular Dynamics International: Company Snapshot
Table 6.13 FUJIFILM Cellular Dynamics International: Recent Developments and Future Outlook
Table 6.14 Lonza: Company Snapshot
Table 6.15 Lonza: Recent Developments and Future Outlook
Table 6.16 Mogrify: Company Snapshot
Table 6.17 Mogrify: Recent Developments and Future Outlook
Table 6.18 REPROCELL: Company Snapshot
Table 6.19 REPROCELL: Recent Developments and Future Outlook
Table 6.20 Stemnovate: Company Snapshot
Table 6.21 Stemnovate: Recent Developments and Future Outlook
Table 6.22 Thermo Fisher Scientific: Company Snapshot
Table 6.23 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Cell Reprogramming Services: List of Partnerships and Collaborations
Table 9.1 Likely Partners for Cell Reprogramming Service and Product Providers in North America
Table 9.2 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
Table 9.3 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
Table 9.4 Likely Partners for Cell Reprogramming Service and Product Providers in North America
Table 9.5 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
Table 9.6 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
Table 11.1 Asgard Therapeutics: Company Snapshot
Table 11.2 Phenocell: Company Snapshot
Table 13.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
Table 13.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
Table 13.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
Table 13.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
Table 13.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
Table 13.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
Table 13.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
Table 13.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
Table 13.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
Table 13.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
Table 13.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Source Cell for iPSC Generation and company size
Table 13.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
Table 13.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of directly reprogrammed cell
Table 13.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
Table 13.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Table 13.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
Table 13.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
Table 13.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
Table 13.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
Table 13.20 Clinical Trial Analysis: Distribution by Trial Status
Table 13.21 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Table 13.22 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.23 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, 2011-2019
Table 13.24 Clinical Trial Analysis: Distribution by Study Design
Table 13.25 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 13.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 13.27 Clinical Trial Analysis: Leading Industry Players
Table 13.28 Clinical Trial Analysis: Analysis by Type of Stem Cell
Table 13.29 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Table 13.30 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.31 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 13.32 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Table 13.33 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Table 13.34 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Table 13.35 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 13.36 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 13.37 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient
Table 13.38 Partnerships and Collaborations: Analysis by Year of Partnership
Table 13.39 Partnerships and Collaborations: Analysis by Type of Partnership
Table 13.40 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Table 13.41 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 13.42 Partnerships and Collaborations: Analysis by Type of Stem Cell
Table 13.43 Partnerships and Collaborations: Analysis by Target Therapeutic Area
Table 13.44 Partnerships and Collaborations: Analysis by Application
Table 13.45 Most Active Players: Distribution by Number of Partnerships
Table 13.46 Partnerships and Collaborations: Regional Analysis
Table 13.47 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.48 Global Cell Reprogramming Services and Products Market, 2020-2030 (USD Million)
Table 13.49 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
Table 13.50 Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030 (USD Million)
Table 13.51 Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030 (USD Million)
Table 13.52 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030 (USD Million)
Table 13.53 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030 (USD Million)
Table 13.54 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
Table 13.55 Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030 (USD Million)
Table 13.56 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030 (USD Million)
Table 13.57 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030 (USD Million)
Table 13.58 Cell Reprogramming Services and Products Market for Other Cells, 2020-2030 (USD Million)
Table 13.59 Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
Table 13.60 Cell Reprogramming Services and Products Market for Research, 2020-2030 (USD Million)
Table 13.61 Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030 (USD Million)
Table 13.62 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
Table 13.63 Cell Reprogramming Services and Products Market in North America, 2020-2030 (USD Million)
Table 13.64 Cell Reprogramming Services and Products Market in Europe, 2020-2030 (USD Million)
Table 13.65 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3P Biopharmaceuticals
2. AA Partners (Ilaya)
3. Abcam
4. ACEA Biosciences
5. Addgene
6. Aegle Therapeutics
7. Allele Biotechnology
8. Alpine BioTherapeutics
9. ALSTEM
10. Altaco XXI
11. American CryoStem
12. Amgen
13. AMS Biotechnology
14. Angel Biotechnology
15. Angiocrine Bioscience
16. Anterogen
17. apceth Biopharma
18. Applied Biological Materials
19. Applied StemCell
20. Asahi Glass
21. Asgard Therapeutics
22. Aspire Health Science
23. Astellas Pharma
24. Athersys
25. Atlantic Bio GMP
26. Axcelead Drug Discovery Partners
27. Axiogenesis
28. Axis Biotec Brasil
29. Axol Bioscience
30. Azidus
31. Bayer
32. Baylx
33. BC Children’s Hospital Research Institute
34. Berlin Institute of Health
35. BHI Therapeutic Sciences
36. Bio Elpida
37. BioCardia
38. Biocenter Finland
39. BioGenCell
40. Bioinova sro
41. BioLamina
42. Biological Industries
43. Bioneer
44. BioNTech IMFS
45. Bioquark
46. BioreclamationIVT
47. BioRestorative Therapies
48. Bit Bio
49. Blood Reprogramming Technologies
50. BlueRock Therapeutics
51. Bone Therapeutics
52. BrainStorm Cell Therapeutics
53. Brigham and Women’s Hospital
54. Broad Institute
55. Bukwang Pharmaceutical
56. Caladrius Biosciences
57. Cancer Genetics
58. Capricor Therapeutics
59. CAR-T (Shanghai) Biotechnology
60. Cedars-Sinai
61. Celgene
62. Celixir
63. Cell and Gene Therapy Catapult
64. Cell Applications
65. Cell Reprogramming & Therapeutics
66. Cell Signaling Technology
67. Cell Tech Pharmed
68. Cell Therapies
69. Cellaria Biosciences
70. Cellerant Therapeutics
71. CELLforCURE
72. CellProthera
73. Cellular Biomedicine Group
74. Cellular Engineering Technologies
75. Cellular Reprogramming
76. Censo Biotechnologies
77. Center for iPS Cell Research and Application, Kyoto University
78. Center for Molecular Medicine, Karolinska University Hospital
79. Center for Regenerative Therapies, German Research Foundation
80. CENTOGENE
81. Cesca Therapeutics
82. CHA Biolab
83. Chabiotech
84. Charles River
85. Chiesi Farmaceutici
86. China Regenerative Medicine International 
87. Cincinnati Children’s Hospital Medical Center
88. Cleans Cells
89. Cognate BioServices
90. Columbia Stem Cell Initiative
91. Cook MyoSite
92. Corestem
93. Creative Bioarray
94. Creative Biolabs
95. Cryosite
96. CureCell
97. Cynata Therapeutics
98. Cytopeutics
99. DefiniGEN
100. DiscGenics
101. Editas Medicine
102. EHL Bio
103. EpiBone
104. Escape Therapeutics
105. ESI BIO
106. European Bank for induced pluripotent Stem Cells
107. European Institute for the Biology of Ageing 
108. Ever Supreme Bio technology
109. Evercyte
110. Evotec
111. Evotec
112. Fate Therapeutics
113. Feinberg School of Medicine
114. Ferrer Internacional
115. Fibrocell Science
116. Fortuna Fix
117. FUJIFILM Cellular Dynamics
118. Gamida Cell
119. GE Healthcare
120. GenCure
121. GeneCopoeia
122. Genenta Science
123. Genome Engineering and iPSC Center 
124. German Stem Cell Research Network
125. GlaxoSmithKline
126. Global Cell Med
127. Gwo xi Stem Cell
128. Harvard Stem Cell Institute
129. Harvard University Stem Cell Institute
130. Hemogenyx
131. Hemostemix
132. Histocell
133. Hitachi Chemical
134. Hope Biosciences
135. Hubei Hongyuan Pharmaceutical technology
136. Human Pluripotent Stem Cell Core Facility
137. Icahn School of Medicine
138. ID Pharma
139. Indiana University
140. Indiana University Research and Technology
141. InSphero
142. Institute of Molecular Biotechnology (IMBA)
143. Institute of Molecular Biotechnology, Austrian Academy of Sceinces
144. International Stem Cell Corporation
145. iPS Academia Japan
146. iXCells Biotechnologies
147. Japan Regenerative Medicine
148. Japan Tissue Engineering
149. Japan Tissue Engineering (J-TEC)
150. jCyte
151. Kadimastem
152. Kangstem Biotech
153. KBI Biopharma
154. Kemwell Biopharma
155. KLSMC Stem Cells
156. K-Stem Cell
157. LAI International
158. Leiden University Medical Center
159. Life & Brain
160. LifeCell
161. Lineage Cell Therapeutics
162. Longeveron
163. Lonza
164. Magellan Stem Cells
165. Magenta Therapeutics
166. MangoGen Pharma
167. MaSTherCell
168. McEwen Stem Cell Institute
169. Med Cell Bahamas
170. Medeor Therapeutics
171. Medicines Discovery Catapult
172. MEDINET
173. Medipost
174. Melbourne Stem Cell Centre
175. Memorial Sloan Kettering Cancer Center 
176. Merck
177. Meridigen Biotech
178. Mesoblast
179. Metrion Biosciences
180. MilliporeSigma
181. Miltenyi Biotec
182. Minovia Therapeutics
183. Mogrify
184. National Eye Institute
185. Nature Cell
186. Ncardia
187. Ncardia 
188. NeuCyte
189. NeuroGeneration
190. New York Blood Center
191. Newcastle University
192. Newcells Biotech
193. NextCell Pharma
194. Nikon CeLL innovation
195. Nipro
196. Nohla Therapeutics
197. Noray Biosciences Group
198. Novadip Biosciences
199. Novartis Pharmaceuticals
200. NuVasive
201. ONO Pharmaceutical 
202. Orchard Therapeutics
203. Orgenesis
204. Orthofix
205. Osiris Therapeutics
206. Oslo University Hospital
207. Ottawa Hospital Research Institute
208. Penn's Institute for Regenerative Medicine
209. Personalized Stem Cells
210. Pharmicell
211. Phenocell
212. Pluriomics
213. Pluristem Therapeutics
214. Plus Therapeutics
215. Promethera Biosciences
216. Propagenix
217. Protide Pharmaceuticals
218. Provia Labs
219. Q Therapeutics
220. R3 Stem Cell
221. Radboudumc Stem Cell Technology Center
222. R-Bio
223. Regeneus
224. Regenexx
225. Reliance Life Sciences
226. ReNeuron
227. ReproCell
228. RheinCell Therapeutics
229. Riordan Technologies
230. Rockland Immunochemicals
231. ROHTO Pharmaceutical
232. Roslin Cells
233. RTI Surgical
234. S.Biomedics 
235. Salvat
236. Samsung BioLogics
237. SanBio
238. Sanofi
239. Sanquin
240. SBH Sciences
241. Sclnow Biotechnology 
242. SCM Lifescience
243. SCM Lifescience
244. Seneca Biopharma
245. Sentien Biotechnologies
246. Shandong Qilu Stem Cells Engineering
247. Shenzhen Hornetcorn Biotechnology
248. Stem Cell Medicine
249. Stem Med
250. STEMCELL Technologies
251. StemCore
252. Stemedica Cell Technologies
253. Stemgenics
254. Steminent Biotherapeutics
255. Stemmatters 
256. Stemnovate
257. Stempeutics Research
258. Stryker
259. Swiss Medica XXI Century
260. System Bioscience
261. Taiwan Bio Therapeutics
262. Taiwan Human Disease iPSC Consortium
263. Takara Bio
264. Takara Bio
265. Takeda
266. Talaris Therapeutics
267. Terumo
268. The Emmes Company
269. The University of California, Irvine
270. The University California, San Diego
271. The University Hospital of Dusseldorf 
272. The University of Wisconsin
273. Thermo Fisher Scientific
274. Tianhe Stem Cell Biotechnologies
275. Tianjin Ever Union Biotechnology 
276. Tianjin Weikai Biological Engineering
277. TICEBA
278. Tocris Bioscience
279. TreeFrog Therapeutics
280. Turn Biotechnologies
281. U.S. Stem Cell
282. United Therapeutics
283. Universal Cells
284. University Medical Center Göttingen
285. University of Bonn
286. University of Cambridge
287. University of Colorado
288. University of Florida College of Medicine
289. University of Helsinki
290. University of Texas
291. University of Utah
292. University of Washington’s Institute for Stem Cell and Regenerative Medicine 
293. University at Buffalo
294. VcanBio Center for Translational Biotechnology
295. Vericel
296. VetStem
297. ViaCyte
298. Viscofan BioEngineering
299. Waisman Biomanufacturing
300. WuXi Advanced Therapies
301. Yale Stem Cell Center
302. YposKesi